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Abstract
Nicotinamide adenine dinucleotide (NAD) is a metabolite essential for cell survival and generated de novo from
tryptophan or recycled from nicotinamide (NAM) through the nicotinamide phosphoribosyltransferase (NAMPT)–
dependent salvage pathway. Alternatively, nicotinic acid (NA) is metabolized to NAD through the nicotinic acid
phosphoribosyltransferase domain containing 1 (NAPRT1)–dependent salvage pathway. Tumor cells are more
reliant on the NAMPT salvage pathway making this enzyme an attractive therapeutic target. Moreover, the thera-
peutic index of NAMPT inhibitors may be increased by in NAPRT-deficient tumors by NA supplementation as
normal tissues may regenerate NAD through NAPRT1. To confirm the latter, we tested novel NAMPT inhibitors,
GNE-617 and GNE-618, in cell culture– and patient-derived tumor models. While NA did not protect NAPRT1-
deficient tumor cell lines from NAMPT inhibition in vitro, it rescued efficacy of GNE-617 and GNE-618 in cell
culture– and patient-derived tumor xenografts in vivo. NA co-treatment increased NAD and NAM levels in
NAPRT1-deficient tumors to levels that sustained growth in vivo. Furthermore, NAM co-administration with
GNE-617 led to increased tumor NAD levels and rescued in vivo efficacy as well. Importantly, tumor xenografts
remained NAPRT1-deficient in the presence of NA, indicating that the NAPRT1-dependent pathway is not reacti-
vated. Protection of NAPRT1-deficient tumors in vivo may be due to increased circulating levels of metabolites
generated by mouse liver, in response to NA or through competitive reactivation of NAMPT by NAM. Our results
have important implications for the development of NAMPT inhibitors when considering NA co-treatment as a
rescue strategy.
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Introduction
In recent years, it has become apparent that altered regulation of cellular
metabolism is an important contributor to cancer cell growth, focusing
attention on identifying critical nodes in metabolic pathways that can
be exploited for therapeutic purposes. One pathway in particular, the
generation of nicotinamide adenine dinucleotide (NAD), provides a
key metabolite that is a critical co-factor and substrate for a wide range
of metabolic enzymes including those required for the generation of
ATP, lipids, and minimizing levels of reactive oxygen species [1].
There are two main processes that cells use to generate NAD: an
elaborate de novo pathway catabolizing dietary tryptophan [2] or two
salvage pathways that use nicotinic acid (NA) or nicotinamide (NAM)
substrates, respectively, to regenerate NAD [3]. These pathways
are dependent on the enzyme nicotinamide phosphoribosyltransferase
(NAMPT ), which catalyzes the condensation of phosphoribosyl pyro-
phosphate (PRPP) and NAM to generate nicotinamide mononucleo-
tide, a key intermediate in the regeneration of NAD [3,4]. Given the
high metabolic demands of proliferating cancer cells [5], it has been
proposed that cancer cells are dependent on the salvage pathways to
continually resupply sufficient levels of NAD required to support
growth. Notably, one of the main NAD-using enzymes, poly(ADP-
ribose) polymerase-1 (PARP-1), uses such high flux of NAD that, when
inhibited, overall cellular NAD levels increase three- to four-fold [6].
Moreover, PARP-1 is frequently upregulated in cancer cells due to
high levels of ongoing DNA damage [7], providing one important factor
for why cancer cells need a continuous supply of NAD. Additionally,
inhibition ofNAMPTwith a small molecule inhibitor effectively reduced
tumor burden in vivo while having minimal impact on normal healthy
tissue [8], again suggesting that tumor cells are more dependent on the
salvage pathway than normal cells.
While cells can potentially use either the de novo or the NAMPT
salvage pathway to generate NAD, a third route is available when
dietary levels of NA are high. In this case, NA is converted to NAD
through three enzymatic steps [9], with the rate-limiting enzyme in
this cascade being nicotinic acid phosphoribosyltransferase domain
containing 1 (NAPRT1). Importantly, some cancer cell lines and
human tumors fail to express NAPRT1 and are thus unable to use this
pathway [8,10,11]. This observation has led to the hypothesis that the
therapeutic index of an NAMPT small molecule inhibitor could be
increased by targeting tumors lacking NAPRT1 and co-treating pa-
tients with NA, thereby protecting normal tissue, but not tumor cells,
from NAMPT inhibition by generating NAD through the NAPRT1-
dependent pathway. Indeed, it has been demonstrated in vitro that NA
cannot rescue the antiproliferative effects of the NAMPT inhibitor
APO866 in NAPRT1-deficient tumor cell lines. Moreover, co-dosing
NA with APO866 at a nontolerated dose in nontumor-bearing mice
resulted in 100% survival and complete protection [8].
Development of two NAMPT inhibitors, APO866 (FK866) and
GMX-1778, has been hindered by poor clinical responses in phase I
clinical trials [12,13]. One approach to increase the clinical response
rate is to identify NAPRT1-deficient tumors and co-administer NA
with the NAMPT inhibitor. For this strategy to succeed, two impor-
tant assumptions need to be met. First, NA should ameliorate the
toxicities associated with systemic NAMPT inhibition. While both
compounds that progressed into phase I clinical trials noted thrombo-
cytopenia as a dose limiting toxicity, in vitro data have shown that
purified human platelets can covert NA to NAD [14], suggesting that
platelets express NAPRT1 and thus may be protected from the effects
of NAMPT inhibition by supplementation with NA. Moreover, con-
sistent with clinical data, dosing APO866 in mice above its maximum
tolerated dose (MTD) also induced thrombocytopenia, but it was
found that co-administration with NA rescued this effect [8]. Thus,
it was proposed that a co-dosing strategy might allow an NAMPT
inhibitor to be dosed higher than was achieved in these early clinical
trials. The second assumption is that co-dosing NA does not reduce
efficacy of an NAMPT inhibitor. In one report, it was shown that co-
dosing NA reduced the antiproliferative effects of an efficacious and
tolerated dose of APO866 in the A2780 (NAPRT1 deficient) ovarian
cancer xenograft model in vivo [8]. In a second study [11], a trend
toward reduced efficacy in the HT-1080 (NAPRT1 deficient) fibro-
sarcoma xenograft model was observed when NA was administered
after treatment with GMX-1777 at its MTD. However, when NA
was co-administered with a dose of GMX-1778 that is not tolerated
in the absence of NA, it rescued lethality and did not affect efficacy
[11]. Therefore, results from in vivo studies conducted with APO866
and GMX-1778 suggests that NA may reduce efficacy of an NAMPT
inhibitor when administered at tolerated doses, although it is unclear
from these two studies to what extent this may occur.
Accordingly, our primary aim was to evaluate the feasibility of a co-
dosing strategy with NA across multiple xenograft models derived from
tissue cell culture and, more clinically relevant, primary patient tumors
that are deficient in NAPRT1. To accomplish this, we evaluated two
novel, potent, and orally bioavailable NAMPT inhibitors, GNE-617
[15] and GNE-618 [16] that is structurally related to GNE-617.
GNE-617 demonstrated robust efficacy in NAPRT1-deficient xeno-
graft models representing fibrosarcoma (HT-1080), prostate (PC3),
and pancreatic (MiaPaCa-2) cancers and inhibited NAD generation
by greater than 98% in vivo. Surprisingly, we found that while co-
administration of NA with GNE-617 did not effectively rescue tumor
growth of these NAPRT1-deficient models in vitro it did in vivo in
all models tested. In addition, NA also reversed in vivo efficacy of
GNE-618 in patient-derived sarcoma and gastric tumor xenografts.
Importantly, NA co-administration with GNE-617 modestly increased
NAD and NAM levels in NAPRT1-deficient tumor xenografts to a
level sufficiently high to maintain tumor growth even in the presence
of NAMPT inhibition. We confirmed that NAD regeneration in
tumor xenografts was not due to reexpression of NAPRT1, suggesting
an in vivo mechanism that reroutes NA to a protection pathway in-
dependent of NAPRT1. Collectively, our data demonstrate that, un-
like observations made in vitro in NAPRT1-deficient tumor cell lines,
administration of NA with NAMPT inhibitors in vivo results in
significant loss of efficacy.
Materials and Methods
Materials
GNE-617 (N -{[4-(3,5-difluorobenzenesulfonyl)phenyl]methyl}
imidazo[1,2-a]pyridine-6-carboxamide) was synthesized by Hande
Sciences (Suzhou, China) as previously described [15]. GNE-618
[N -(4-((3-(trifluoromethyl)phenyl)-sulfonyl)benzyl)-1H -pyrazolo
[3,4-b]pyridine-5-carboxamide] was prepared by Medicilon, Inc
(Shanghai, China) as previously described [16]. NA and NAM were
purchased from Sigma-Aldrich (St Louis, MO).
Cell Lines and Viability Assays
Cell lines were obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA) or Deutsche Sammlung von Mikroorga-
nismen und Zellkulturen (DSMZ, Braunschweig, Germany),
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expanded, and stored at early passage in a central cell bank. Lines were
authenticated by short tandem repeat and genotyped on reexpansions.
Cells were grown in RPMI 1640 supplemented with 10% FBS and 2
mM glutamine (Invitrogen, Grand Island, NY) and passaged no more
than 20 times after thawing. To determine 50% effective concentration
(EC50) values, cells were plated such that 30% to 40% confluency was
achieved the next day. Nine-point dose titrations of GNE-617 were
added directly to the cells, and after 96 hours, cell viability was quan-
tified using CyQUANT Direct Cell Proliferation Assay (Invitrogen,
Ltd) that measures nucleic acid in live cells, followed by CellTiter-
Glo Luminescent Cell Viability Assay (Promega Corporation, Madi-
son, WI) that measures ATP levels. EC50 values were calculated with
a four-parameter fit using XLfit 5.1 (ID Business Solutions, Ltd, La
Jolla, CA) or Prism 5.04 (GraphPad Software Inc, La Jolla, CA).
In Vivo Studies
All in vivo efficacy and imaging studies were approved by Genentech’s
Institutional Animal Care and Use Committee and adhere to the
National Institutes of Health Guidelines for the Care and Use of
Laboratory Animals. Tumor xenografts derived from cell lines were
established by subcutaneous injection of cells in female NCR nude mice
(Taconic Farms, Oxnard, CA). Patient-derived tumors from the SAO-
737 sarcoma and STO-399 gastric models were implanted as fragments
into female BALB/c SCID mice at CrownBio (Santa Cruz, CA) and
Pharmaron (Beijing, China), respectively. Animals were distributed into
treatment groups when tumors reached a mean volume of approximately
150 to 300 mm3. GNE-617, GNE-618, and GMX-1778 were formu-
lated in polyethylene glycol (PEG) [PEG400/H2O/EtOH (60/30/10,
vol/vol/vol)], while NA and NAM were dissolved in sterile water as
vehicles. Test articles were administered by oral gavage. NA and NAM
were administered twice daily, while NAMPT inhibitors were dosed
either twice daily or once daily. NAMPT inhibitors were dosed before
NA treatment. Tumor volumes were determined using digital calipers
(Fred V. Fowler Company, Inc, Newton, MA) using the formula (L ×
W × W )/2. Curve fitting was applied to log2 transformed individual
tumor volume data using a linearmixed-effects model with the R package
nlme, version 3.1-97 in R v2.13.0 (R Development Core Team 2008;
R Foundation for Statistical Computing, Vienna, Austria) [17]. Tumor
growth inhibition (%TGI) was calculated as the percentage of the area
under the fitted curve (AUC) for the respective drug-treated group per day
relative to vehicle control animals, %TGI = 100 × (1 − (AUCtreatment/day)/
(AUCvehicle/day)); 100% TGI was defined as tumor stasis, while
values greater than 100% TGI indicate tumor regression. Fitted
tumor volume data are reported as %TGI with 95% confidence
intervals (CIs; lower and upper range). Tumor sizes and body weights
were recorded twice weekly over the course of the study. Mice with
tumor volumes ≥2000 mm3 or recorded body weight loss ≥20%
from their weight at the start of treatment were promptly killed.
An MTD was defined as the dose in which <20% body weight loss
or no animal deaths were observed.
For fluoro-deoxyglucose (FDG)–PET imaging studies, PC3 prostate
cancer xenografts were established by subcutaneous injection in the
right flank of nude mice. When tumors reached a mean volume of
300 to 350 mm3, mice were imaged on Siemens Inveon MM PET/
CT scanners (Siemens Preclinical Solutions, Knoxville, TN). Animals
were lightly anesthetized for restraint with approximately 3.5% sevo-
flurane in air and body temperature maintained at 37°C by warm air-
flow under feedback control. Animals were fasted overnight with access
to water and kept on warming pads before imaging. At scan onset,
mice received an 18-FDG tracer dose of approximately 300 mCi
by 60-second infusion through a lateral tail vein catheter. For every
scan, blood glucose was measured pre-scan and post-scan with
a Bayer Contour glucometer (Bayer Healthcare, Tarrytown, NY).
Tumor volumes were measured daily over the treatment period as
described above.
The imaging protocol consisted of a 30-minute dynamic acquisi-
tion immediately followed by an X-ray computed tomography (CT)
used for anatomic reference and attenuation correction. List mode
data were reconstructed into images with 128 × 128 in-plane voxels
of 0.4 × 0.4 mm and 0.8 mm through-plane voxel thickness using
vendor-provided iterative OP-MAP implementation with the beta
hyperparameter set to 0.05. Regions of interest (ROIs) were drawn
using Inveon Research Workplace (Siemens Preclinical Solutions) soft-
ware. Tumor ROIs were defined as voxels exceeding a 50% threshold
of the maximal tumor signal, thus excluding necrotic regions from the
analysis. Mean signal values from drawn ROIs were used for Patlak-
Gjedde analysis with liver ROIs used as a blood reference tissue [18].
Calculations were computed with statistical programming language R
(R Development Core Team. R: A Language and Environment for Sta-
tistical Computing. The R Foundation for Statistical Computing,
Vienna, Austria; R version 2.15.2, 2012). The metabolic tumor glucose
uptake rate, MRGluc
MAX, is calculated as K i * (mean blood glucose +
Km), where K i is the tumor FDG uptake rate constant and Km is the
half-saturation Michaelis-Menten constant set to 130 mg/dl [19].
Metabolite Analysis
Concentrations of NA, NAM, and NAD in mouse blood, cell
line, tumor, and liver were determined by a nonvalidated liquid
chromatography–tandem mass spectrometry (LC-MS/MS) assay.
Due to different sample treatment requirements, NA and NAM use
one set of sample, while NAD uses the second set of sample. For
NA and NAM analyses, tumor and liver tissues were homogenized
by using a FastPrep-24 bead beater (MP Biomedicals, Solon, OH).
NA-13C6 and NAM-d4 were used as surrogate analytes for NA and
NAM, respectively. All homogenate, blood, and cell line samples
were crashed with acetonitrile, and the supernatant was injected into
LC-MS/MS. For NAD analysis, all samples, including blood, cell line,
tumor, and liver samples, were treated with PCA before extraction or
homogenization. These treated homogenate, blood, and cell line sam-
ples were crashed with PCA again. The supernatant was diluted with
5 mM ammonium formate and injected into LC-MS/MS. Sample
analysis was carried out with a Shimadzu Nexera (Columbia, MD)
coupled to an API 5500 Q trap Mass Spectrometer (AB Sciex, Foster
City, CA) equipped with a turbo electrospray interface in positive
ionization mode. LC-MS/MS data were acquired using Analyst
software (v1.42; AB Sciex).
Ex Vivo Clonogenic Growth Assay
Single cell suspensions of tumor xenografts that were grown in
mice were generated by mechanical disassociation and disaggrega-
tion with an enzyme cocktail containing collagenase and DNase;
40,000 cells in 0.35% agar were layered on 0.5% agar in 24-well plates
and cultured for 24 hours before treatment. Cells were treated with
DMSO vehicle or escalating concentrations of GNE-618 for a period
of 14 days with medium supplementation weekly. At the end of the
treatment period, colonies were stained with calcein AM crystal violet
dye and fixed in 10% neutral buffered formalin. The Acuman imaging
analysis system was used to quantify colony numbers and size.
1316 Nicotinic Acid Rescues NAMPT Inhibition In Vivo O'Brien et al. Neoplasia Vol. 15, No. 12, 2013
Western Blot Analysis
Tumor xenografts were treated with extraction buffer (Invitrogen,
Camarillo, CA) containing 10 mM Tris (pH 7.4), 100 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM Na4P2O7, 2 mM
Na3VO4, 1% Triton X-100, 10% glycerol, 0.1% sodium dodecyl
sulfate, and 0.5% deoxycholate supplemented with phosphatase
and protease inhibitors (Sigma-Aldrich) and 1 mM PMSF to gener-
ate lysates. Protein concentration was determined from lysates using
BCA protein assay (Pierce, Rockford, IL). Proteins were resolved by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose membranes (Invitrogen, Camarillo, CA). Mem-
branes were hybridized with the following primary antibodies:NAMPT
(MBL International Corporation, Woburn, MA) and NAPRT1
(Sigma-Aldrich). LI-COR Odyssey Infrared detection system (LI-
COR, Lincoln, NE) was used to detect and assess protein expression.
Statistical Analysis
For comparisons between treated groups, an unpaired t test assuming
unequal variances was used; for three or more groups, a comparison
to controls using Dunnett method was used. All summary statistics
of the results are given as means ± SEM or SD.
Results
GNE-617 Is a Potent NAMPT Inhibitor that Reduces
Cellular NAD and ATP and Promotes Cell Death in
NAPRT1-Proficient and NAPRT1-Deficient Tumor
Cells In Vitro
GNE-617 is potent and competitive NAMPT inhibitor with a
biochemical half-maximal inhibitory concentration (IC50) of 5 nM
[15]. We compared the ability of GNE-617 to deplete NAD levels
in a set of cell lines that we confirmed to be NAPRT1-deficient
[PC3 (prostate), HT-1080 (fibrosarcoma), MiaPaCa-2 (pancreatic)]
and NAPRT1-proficient [HCT-116 (colorectal), Colo205 (colorectal),
Calu6 (non–small cell lung cancer)] based on protein expression
(FigureW1A). Treatment ofNAPRT1-deficient andNAPRT1-proficient
cell lines with GNE-617 resulted in a >95% reduction in NAD
levels within 48 hours and associated EC50 values ranged from 0.54
to 4.69 nM (Table 1).We also evaluated the potency of GNE-617 with
regard to reduction in ATP levels and cellular viability in these same
cell lines. Regardless of NAPRT1 status, GNE-617 reduced ATP levels
and cellular viability with EC50 values from 2.16 to 9.35 nM and 1.82
to 5.98 nM, respectively (Table 1).
GNE-617 Induces Robust Antitumor Responses and
Reduces NAD Levels in NAPRT1-Proficient and
NAPRT1-Deficient Xenograft Models In Vivo
Given the potency of GNE-617 in vitro, we determined its efficacy
in xenograft models that were NAPRT1-proficient (HCT-116) and
NAPRT1-deficient (MiaPaCa-2, PC3, and HT-1080; Figure 1).
GNE-617 was highly efficacious and induced tumor regression within
5 days of twice daily treatment at MTDs of 10 to 15 mg/kg (20 to
30 mg/kg total dose/day) in the HCT-116 [%TGI at 15 mg/kg, twice
daily = 87 (95% CI = 78, 94)], MiaPaCa-2 [%TGI at 10 mg/kg, twice
daily = 91 (95% CI = 87, 95)], PC3 [%TGI at 15 mg/kg, twice daily =
168 (95% CI = 122, 476)], and HT-1080 [%TGI at 15 mg/kg,
twice daily = 143 (95% CI = 107, 438)] xenograft models (Figures 1,
A–D, and W2). Efficacy of GNE-617 increased in a dose-dependent
fashion and confirmed on a once daily schedule at doses that were well
tolerated in the PC3 [%TGI, once daily at 5 mg/kg = 2 (95% CI =
0.6, 3.0); 7.5 mg/kg = 58 (95% CI = −118,115); 10 mg/kg, once
daily = 137 (95% CI = 111, 215); 20 mg/kg = 147 (95% CI = 118,
242); 30 mg/kg = 144 (95% CI = 118, 232)] and HT-1080 [%TGI,
once daily at 5 mg/kg = 8 (95% CI = 1.0, 15.0); 7.5 mg/kg = 31 (95%
CI = −176, 83); 10 mg/kg, once daily = 66 (95% CI = −89, 107);
20 mg/kg = 138 (95% CI = 113, 228); 30 mg/kg = 143 (95% CI =
112, 252)] xenograft models (Figures 1, E and F , and W2). Notably,
increased tumor regressions were observed within 7 days of daily
administration of GNE-617, which were maintained after dosing con-
cluded on day 7 (Figure 1, E and F ). Regardless of dosing schedule
(i.e., twice daily vs once daily), robust efficacy, defined by tumor
regressions, was observed within 5 to 7 days of treatment in vivo
when a total MTD of 20 to 30 mg/kg GNE-617 was administered.
The pharmacodynamics of GNE-617 was assessed within 24 hours
after single dose treatment. A significant decrease in tumor NAD levels
was observed within 12 hours of treatment, and by 24 hours, NAD
was reduced to 85% of control levels in PC3 or HT-1080 tumors
(Figure 2, A and B). In the HT-1080 xenograft model, the reduction
of NAD by GNE-617 was dose-dependent with greater than 98% in-
hibition observed after five daily doses of 20 or 30 mg/kg, doses that
corresponded with maximum efficacy (Figures 1F and 2C ). Interest-
ingly, 5 and 7.5 mg/kg of GNE-617 significantly reduced NAD levels
by 80% after 5 days of treatment but did not lead to tumor growth
inhibition (Figures 1F and 2C). Moreover, maximum antitumor activ-
ity required sustained inhibition ofNAMPT because >95% reduction of
tumor NAD levels was achieved within 3 days of GNE-617 treatment
and maintained over a period of 7 days, whereas tumor regressions were
observed only after 5 days of dosing (Figure 2D). The latter observation
suggests that maximum efficacy of GNE-617 is dependent on a sus-
tained reduction of NAD by greater than 95% for at least 5 days.
Co-administration of NA with NAMPT Inhibitors
Protects NAPRT1-Deficient Tumors In Vivo
To evaluate the utility of exogenous NA administration to protect
normal tissues, we co-administered NA with GNE-617 in NAPRT1-
deficient and NAPRT1-proficient tumor cells in vitro and in vivo. NA
protected NAPRT1-proficient HCT-116 cells from NAMPT inhibi-
tion (0.2 μM GNE-617) in a dose-dependent manner in vitro (NA
EC50 = 0.41 μM; Figure 3A). A similar level of protection was also
observed in vivo, as co-administration of NA (100 mg/kg, twice daily)
rescued the antitumor effects of GNE-617 when dosed at the MTD in
the HCT-116 xenograft model [%TGI without NA = 119 (95% CI =
101, 147); %TGI with NA = 4 (95% CI = 0.1, 44); Figure 3B]. As
Table 1. Cellular Potency of GNE-617 in NAPRT1-Proficient and NAPRT1-Deficient Tumor
Cell Lines.
Tumor Model NAPRT1 Status Cellular EC50
NAD ATP Viability
HCT-116 Proficient 1.03 ± 0.10 2.16 ± 0.83 1.82 ± 0.64
Colo205 Proficient 0.54 ± 0.01 5.31 ± 1.93 4.44 ± 1.29
Calu6 Proficient 1.99 ± 0.04 3.90 ± 1.12 4.52 ± 1.77
PC3 Deficient 1.06 ± 0.30 3.46 ± 2.05 2.98 ± 2.17
HT-1080 Deficient 1.05 ± 0.10 2.49 ± 1.71 2.58 ± 1.50
MiaPaCa-2 Deficient 4.69 ± 0.20 9.35 ± 4.86 5.98 ± 2.17
Tumor cell lines were treated with a nine-point dose titration of GNE-617 for 48 hours, and NAD
levels were measured by LC-MS/MS as described in Materials and Methods section. Values reported
are effective concentrations that cause a 50% reduction (EC50) in NAD, ATP, or cell viability ± SDs.
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Figure 1. GNE-617 is efficacious inNAPRT1-proficient andNAPRT1-deficient tumor xenograft models. (A–D)NAPRT1-proficient (A, HCT-116)
and NAPRT1-deficient (B, MiaPaCa-2; C, PC3; D, HT-1080) xenograft models were treated (Rx) orally with control (vehicle) or GNE-617 at
the doses indicated for 5 days (twice daily). PC3 (E) and HT-1080 (F) tumor xenografts were treated orally with GNE-617 at the doses
indicated for 7 days (once daily).
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PC3 tumor cells lack NAPRT1, co-dosing of NA (100 mg/kg, twice
daily) did not prevent the antiproliferative effects of NAMPT inhibi-
tion in the presence of GNE-617 in vitro (NA EC50 > 100 μM;
Figure 3C ) but surprisingly did when grown as xenografts in vivo
[%TGI without NA = 119 (95% CI = 101, 147); %TGI with
NA = 4 (95% CI = 0.1, 44); Figure 3D]. Moreover, co-administration
of a lower dose of NA (30 mg/kg, twice daily) that, in mouse blood,
mimics the human exposure of a prescribed dose of 2000 mg of niacin
[20] also rescued efficacy of GNE-617 in the PC3 xenograft model
[%TGI without NA = 119 (95% CI = 101, 147); %TGI with NA =
6 (95% CI = −0.1, 22); Figure 3D]. Additionally, continuous once
daily dosing of GNE-617 for 21 days did not overcome the protective
effects of NA in the PC3 xenograft model [%TGI without NA = 93
(95% CI = 86, 97); %TGI with NA = 12 (lower, upper CI = −20,
39); FigureW3A]. Importantly, the loss of efficacy by NA co-treatment
is not unique to GNE-617, as a similar loss of efficacy was observed
with the structurally distinct NAMPT inhibitor, GMX-1778 (8)
[%TGI without NA = 138 (95% CI = 118, 200); %TGI with NA =
7 (95% CI = 1, 32); Figure W3B].
To confirm the protective effects of NA observed in NAPRT1-
deficient PC3 tumor cells, we examined two additional NAPRT1-
deficient cell lines (HT-1080 and MiaPaCa-2) and found that these
cell lines remained sensitive to GNE-617 in the presence of NA in vitro
(NA EC50 > 100 μM; Figure 3, E and G). However, NA completely
prevented GNE-617–induced TGI in vivo in the MiaPaCa-2 [%TGI
without NA = 77 (95% CI = 41, 96); %TGI with NA = 2 (95% CI =
0.05, 37); Figure 3F ]. Notably, NA alone induced tumor growth
delay but in the HT-1080 model only [%TGI of NA = 60 (95%
CI = 14, 141)]. However, co-administration of GNE-617 with NA
rescued TGI to levels observed with NA alone [%TGI without NA =
139 (95% CI = 107, 674); %TGI with NA = 69 (95% CI = 15, 147);
%TGI of NA = 60 (95% CI = 14, 141); Figure 3H ]. Interestingly,
Figure 2. GNE-617 reduces tumor NAD levels in NAPRT1-deficient tumor xenograft models. PC3 (A) and HT-1080 (B) xenografts were
treated orally with a single dose of GNE-617 (30 mg/kg), and tumors were harvested at 12 and 24 hours post-dose. NAD levels were mea-
sured by LC-MS/MS as described in Materials and Methods section. (C) HT-1080 xenografts were treated orally for 5 days with GNE-617
at the doses indicated, and tumors were harvested 1 hour following the final dose for NAD measurements by LC-MS/MS. (D) HT-1080
xenografts were treated orally with 30 mg/kg GNE-617, and tumors were harvested 1 hour after the final dose on days 1, 3, 5, and 7 for
NAD measurement by LC-MS/MS. Tumor volumes were measured at the days indicated as described in Materials and Methods section.
Comparisons between treated groups and control (vehicle) were determined by Dunnett method: **P < .001 and ***P < .0001. Compari-
sons between treatment groups were performed using unpaired t test assuming unequal variances: #P < .01 and ##P < .001.
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Figure 3. Co-administration of NA with GNE-617 protects NAPRT1-deficient tumors in vivo. NAPRT1-proficient (A, HCT-1116) and NAPRT1-
deficient (C, PC3; E, MiaPaCa-2; G, HT-1080) tumor cell lines were exposed to 0.2 μM GNE-617 and a dose range of NA (0-100 μM) for
96 hours, and cell viability was measured by the CyQUANT assay as described in Materials and Methods section. NAPRT1-proficient (B,
HCT-116) and NAPRT1-deficient (D, PC3; F, MiaPaCa-2; H, HT-1080) tumor xenograft models were treated (Rx) orally with control (vehicle),
NA (100 and 30mg/kg, twice daily), GNE-617, or a combination of both agents at the doses indicated for 5 days. GNE-617 was administered
twice daily in the HCT-116 and PC3 xenograft models and once daily in the HT-1080 and MiaPaCa-2 xenograft models.
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Figure 4. NA rescues in vivo efficacy of GNE-618 in primary patient-derived tumor xenograft models. (A) SAO-737 sarcoma patient-
derived tumor explants were grown ex vivo as described in Materials and Methods section and treated with DMSO vehicle control
or escalating doses of GNE-618 as shown for 14 consecutive days. Following treatment, cells were stained for viability by calcein
AM crystal violet dye and colony number was enumerated microscopically. (B) SAO-737 sarcoma patient-derived tumor explants were
treated with DMSO vehicle control, 10 μM NA, 37 nM GNE-618, or the combination of GNE-618 and NA for 14 consecutive days.
Following treatment, cells were stained with calcein AM crystal violet dye to determine viability. (C and D) SAO-737 sarcoma (C) and
STO-399 gastric (D) patient-derived tumor xenografts were treated (Rx) orally with vehicle control, GNE-618 daily, NA (twice daily), or the
combination of GNE-618 and NA for a period of 5 days.
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lower doses of NA (30 mg/kg, twice daily) also conferred protection
against GNE-617 in the MiaPaCa-2 model [%TGI without NA = 77
(95%CI = 41, 96); %TGI with NA = 4 (95%CI = −5, 17); Figure 3F]
but not in the HT-1080 model [%TGI without NA = 139 (95% CI =
41, 96); %TGI with NA = 115 (95% CI = 8, 301); %TGI of NA
only = 60; Figure 3H].
To translate our findings in these cell culture–derived xenograft
models, we also evaluated the ability of NA to rescue NAMPT inhibi-
tion in vivo in patient-derived xenograft models that are more repre-
sentative of the heterogeneity observed in patient tumors. We initially
confirmed that NAPRT1 was not expressed in sarcoma (SAO-737)
and gastric cancer (STO-799) primary patient tumors (Figure W1B).
For in vivo efficacy studies using these patient-derived xenograft mod-
els, we also tested another novel and orally bioavailable NAMPT
inhibitor, GNE-618 that is structurally related to GNE-617 [16].
Additionally, we recently demonstrated that GNE-618 is efficacious
in cell culture– and patient-derived xenograft models that are NAPRT1
proficient and, as a result, is rescued when NA is co-administered
in vivo [21]. We were able to establish growth of the SAO-737 sar-
coma model ex vivo and determined that it was indeed sensitive to
GNE-618 (cell viability EC50 = 3.7 nM) and comparable to the
potency of GNE-617 in cell-cultured tumor cell lines (Figure 4A). Simi-
lar to our in vitro observations, NA was unable to rescue SAO-737
tumors from the antiproliferative effects of GNE-618 ex vivo (Fig-
ure 4B). However, in vivo, NA completely protected the patient-
derived sarcoma tumor xenograft model from the antitumor effects of
GNE-618 when dosed at its MTD of 100 mg/kg [%TGI without
NA = 75 (95% CI = 21, 97); %TGI with NA = 13 (95% CI = −187,
51); Figure 4C]. Moreover, the loss of efficacy of GNE-618 with NA
co-treatment was also observed in the STO-399 gastric cancer xeno-
graft model [%TGI without NA = 95 (95% CI = 82, 104); %TGI with
NA = 11 (95% CI = −40, 44); Figure 4D]. Thus, co-treatment of NA
with three different NAMPT inhibitors results in loss of in vivo efficacy
in both cell culture– and patient-derived xenograft models that are
NAPRT1 deficient.
To pharmacodynamically confirm our findings that NA can rescue
TGI induced by GNE-617 in vivo, we employed FDG-PET imaging
to probe tumor growth in the presence and absence of NA. PC3
tumor xenografts were imaged for FDG tracer uptake on day 0 (pre-
treatment baseline) and 4 days after daily treatment with GNE-617
alone or in combination with NA. A trend toward TGI was observed at
day 4 as previously observed (Figures 1E and 5) with a concomitant
Figure 5. GNE-617 decreases FDG uptake in PC3 tumor xenografts, which is reversed by NA co-treatment. (A–C) PC3 tumor xenografts
grown in the hind flank were treated (Rx) orally with vehicle (control), GNE-617, NA, or the combination of NA and GNE-617 for 4 days at
the doses indicated. Animals were dosed with 18-FDG tracer as described in Materials and Methods section. Changes in tumor volume
(A), FDG uptake (B, MRGluc
MAX), and mean blood glucose levels (C) were measured as described in Materials and Methods section.
(D) Maximum image projections of FDG-PET uptake in tumor tissue from representative animals at day 0 (pre-treatment baseline) and
day 4 across the four treatment groups as shown. Arrows designate location of tumors. Colorimetric scale denotes degree of FDG-PET
uptake with upper limits defined in the yellow range. Comparisons between treated groups and vehicle control were performed by Dunnett
method: *P < .05, ***P < .0005.
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Figure 6. NA co-administration with GNE-617 in NAPRT1-deficient tumors increases tumor NAD and NAM levels in vivo. MiaPaCa-2 (A),
PC3 (B), and HT-1080 (C) tumor xenografts (n = 5 per model) were treated with vehicle (control), NA (100 and 30 mg/kg, twice daily),
GNE-617 (once daily), or the combination of both agents at the doses shown for 5 days, and tumors were harvested 1 hour following the
final dose for measurement of NAD levels by LC-MS/MS as described in Materials and Methods section. MiaPaCa-2 (D), PC3 (E), and
HT-1080 (F) tumor xenografts (n = 5 per group) were treated with vehicle (control), NA (100 and 30 mg/kg, twice daily), GNE-617, or the
combination of both agents for 5 days, and tumors were harvested 1 hour following the final dose for measurement of NAM levels by
LC-MS/MS as described in Materials and Methods section. Comparisons between treated groups and control (vehicle) were determined
by Dunnett method: ***P < .0001. Comparisons between treatment groups were performed using unpaired t test assuming unequal
variances: #P < .01.
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decrease in MRGluc
MAX by 60% for GNE-617 alone compared with
the control group (Figure 5, A, B, and D). Co-treatment with NA
returned the GNE-617–inhibited glucose metabolic rate to nontreated
levels (Figure 5, B and D). Modest hyperglycemic effects that were
observed in mouse blood with GNE-617 dosing as a result of de-
creased glucose uptake were also reversed when NA was administered
in parallel (Figure 5C).
NA Co-administration with GNE-617 in NAPRT1-Deficient
Tumors Increases Tumor NAD and NAM Levels In Vivo
Given that NAD is essential for tumor cell growth and metabolism,
the lack of efficacy when GNE-617 was co-dosed with NA in
NAPRT1-deficient xenograft models suggested that NAD levels remain
high in tumors. To test this hypothesis, we evaluated NAD levels in
tumor xenografts after 5 days of NA (100 and 30 mg/kg) co-treatment
with GNE-617 in the HT-1080, MiaPaCa-2, and PC3 models. Con-
sistent with our previous results, we confirmed that GNE-617 treat-
ment resulted in a 98% reduction in tumor NAD levels in all three
models when compared to vehicle control levels after 5 days of treat-
ment (Figure 6, A–C ). Interestingly, compared to GNE-617 treatment
alone, tumor NAD levels increased significantly by 15% to 25% in
the MiaPaCa-2, PC3, and HT-1080 xenograft models when NA
(100 mg/kg) was co-administered with GNE-617 (P < .01 vs GNE-
617 treatment alone; Figure 6, A–C). Notably, even though co-dosing
NA with GNE-617 increased NAD levels, tumor NAD levels were
still significantly reduced by 80% (P < .0001 vs vehicle control; Fig-
ure 6, A–C ). Similar observations were made with NA dosed at
30 mg/kg in the PC3 and MiaPaCa-2 xenograft models (Figure 6, A
and B). However, NA at 30 mg/kg did not significantly increase tumor
NAD levels in the HT-1080 xenograft model when compared to
GNE-617 treatment alone (Figure 6C ). The latter observation relates
to the inability of this dose of NA to rescue the efficacy of GNE-617 in
the HT-1080 xenograft model and, remarkably, suggests that a reduc-
tion of tumor NAD levels by 75% to 85% is sufficient to maintain
robust in vivo growth even in the presence of NAMPT inhibition.
Given that NAD is directly converted to NAM by NAD-using en-
zymes such as PARP, we next examined if NA (100 and 30 mg/kg)
also resulted in an increase in tumor NAM levels in NAPRT1-deficient
models. GNE-617 treatment alone significantly reduced NAM level in
MiaPaCa-2, PC3, and HT-1080 tumors by ∼98% relative to vehicle-
treated animals consistent with a comparable decrease in NAD levels
in these models (Figure 6, D–F ). Notably, compared to GNE-617
alone, co-treatment of GNE-617 with NA in these models also in-
creased tumor NAM levels to ∼25% of vehicle control levels (Figure 6,
D–F ). Again, similar observations were made with NA dosed at
30 mg/kg in the PC3 and MiaPaCa-2 xenograft models but not in
the HT-1080 xenograft model (Figure 6, D–F).
We next examined the possibility that generation of NAD, and sub-
sequently NAM, in NAPRT1-deficient tumors was due to NAPRT1
reexpression in tumor xenografts. We did not observe reexpression
of NAPRT1 in either the PC3, HT-1080, or MiaPaCa-2 xenograft
models after 5 days of treatment with NA, GNE-617, or a combination
of both agents (Figure 7, A–C ), suggesting that NAPRT1 reexpres-
sion may not be driving NAD generation in vivo in response to NA.
An alternative hypothesis is that NAD or NAM may be provided
exogenously by highly metabolic normal tissue such as the liver. We
did observe a significant increase in liver NAD and NAM levels after
treatment with NA alone or when co-administered with GNE-617 in
NAPRT1-deficient tumor-bearing animals (P < .0001 vs vehicle treat-
ment; Figure 8, A and B). In addition, compared to GNE-617 treat-
ment alone, we also observed that NAD and NAM levels significantly
increased inmouse blood after co-treatment with NA (P < .01 for NAD
and P < .001 for NAM vs GNE-617 treatment only; Figure 8, C and
D). Thus, normal metabolic tissue, such as liver, may produce metabo-
lites such as NAD and NAM that can subsequently be provided to
NAPRT1-deficient tumors exogenously, thereby bypassing the require-
ment for conversion of NA by NAPRT1.
NAM Can Rescue Antitumor Effects of NAMPT Inhibition
In Vitro and In Vivo
Because NAM is the natural substrate of NAMPT, high levels of
NAM can affect the ability of NAMPT inhibitors to block enzymatic
activity [15]. Given that we observed an increase in tumor NAM levels
with NA co-administration, we reasoned that protection fromNAMPT
inhibition might be provided by the substrate NAM itself, which
may compete with GNE-617 for binding to NAMPT. We initially
determined if NAM could protectNAPRT1-deficient cells in vitro from
NAMPT inhibition by examining NAD levels in PC3 and MiaPaCa-2
cells that were treated with GNE-617 in the presence or absence of
NAM. Surprisingly, NAM modestly increased NAD levels in the pres-
ence of GNE-617 in both cell lines to ∼15% relative to GNE-617
treatment alone in vitro (Figure 9, A and B). In contrast, NA alone
was unable to increase NAD levels in the presence of GNE-617 con-
firming that these tumor cell lines were indeedNAPRT1-deficient (Fig-
ure 9, A and B). We also compared the ability of NAM to rescue cell
viability in vitro. While GNE-617 significantly reduced ATP levels and
Figure 7. Expression of NAMPT and NAPRT1 in tumor xenografts
after treatment with NA. NAMPT and NAPRT1 protein expression
was determined in PC3 (A), HT-1080 (B), and MiaPaCa-2 (C) tumor
xenografts after 5 days of treatment with vehicle control, 100 mg/
kg NA, 30 mg/kg GNE-617, or the combination of both agents by
Western blot analysis as described in Materials and Methods sec-
tion (n = 4 animals per group). Colo205 tumor cell lysates were
included as positive controls for NAPRT1 expression.
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viability in both PC3 and MiaPaCa-2 cell lines, co-administration of
NAM, but not NA, with GNE-617 remarkably protected cells from
significant depletion of ATP and loss of viability (Figure 9, C–F). Col-
lectively, our in vitro and in vivo results indicate that small increases in
tumor NAD levels induced by NAM were sufficient to protect against
the antitumor effects of GNE-617. Remarkably, tumor growth can
be maintained even when tumor NAD levels are reduced by ∼85%
relative to untreated animals.
To corroborate the rescuability of NAM in vitro, NAM was co-
dosed with GNE-617 for 5 consecutive days in the PC3 xenograft
model. Consistent with our in vitro results, NAM was able to rescue
the antitumor effects of GNE-617 in vivo [%TGI without NAM =
130 (95% CI = 110, 221); %TGI with NAM = 42 (95% CI = −198,
93); %TGI of NAM only = 39 (95% CI = −195, 91); Figure 10A].
As expected for a model that is dependent only on NAMPT for NAD
production, administration of NAM alone in vivo resulted in a sig-
nificant increase in tumor NAD and NAM levels relative to vehicle
control–treated animals (P < .0001; Figure 10, B and C ). Similar to
NA, NAM co-treatment with GNE-617 also resulted in a modest
but significant increase in tumor NAD and NAM levels when com-
pared to GNE-617 alone (P < .0001 for tumor NAD and P < .001
for tumor NAM; Figure 10, B and C ). We confirmed that circulat-
ing levels of NAM in mouse blood remained significantly elevated on
NAM co-administration when compared to tumor-bearing animals
treated with GNE-617 alone (P < .0001 vs GNE-617 treatment
only; Figure 10D). Thus, similar to NA, NAM can rescue TGI induced
by GNE-617 and increase tumor NAD to levels that are sufficient to
maintain growth in vivo.
Discussion
NAD serves as a co-enzyme for metabolic pathways that generate
ATP as well as contribute to DNA repair mechanisms and is there-
fore critical for tumor cell survival. Given the high metabolic and
Figure 8. NA increases liver and blood NAD and NAM levels in vivo. PC3 tumor-bearing xenografts (n = 5 per group) were treated with
vehicle, NA, GNE-617 or the combination of both agents for 5 days with the indicated doses and mouse liver (A and B) and blood (C and D)
collected 1 hour following the final dose formeasurement of NAD (A andC) andNAM (B andD) levels by LC-MS/MSas described inMaterials
and Methods section. Comparisons between NA-treated groups and control (vehicle) was determined by Dunnett method: ***P < .0001.
Comparisons between treatment groups were performed using unpaired t test assuming unequal variances: #P < .01, ##P < .001.
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bioenergetic demands of proliferating cancer cells [5], it has been pro-
posed that cancer cells are dependent on NAD salvage pathways driven
by the rate-limiting enzymes NAMPT and NAPRT1, as opposed to
de novo synthesis, to continually supply sufficient levels of NAD
required to support growth and survival. However, tumors that are
deficient inNAPRT1 are unable to use one of the two salvage pathways
making them more dependent on NAMPT for NAD generation and
thus survival [8,10,11]. Normal cells, on the other hand, can use NA
to generate NAD through the NAPRT1-proficient salvage pathway,
thereby mitigating the effects of NAMPT inhibition [9]. Thus, it
has been proposed that a wider therapeutic index may be achieved
when NA is co-administered with NAMPT inhibitors. However,
NA co-treatment should not compromise the efficacy of NAMPT
inhibitors in tumors that remain NAPRT1 deficient. Therefore, the
primary goal of our study was to confirm whether supplementation
with NA can indeed preserve efficacy of two novel NAMPT inhibi-
tors (GNE-617 and GNE-618) across multiple xenograft models
derived from tumor cells as well as primary patient samples that were
NAPRT1 deficient.
In vitro sensitivity to GNE-617 translated into robust efficacy char-
acterized by tumor regressions in the corresponding xenograft models.
We also observed that greater than 95% reduction of tumor NAD
levels occurred within 3 days of GNE-617 treatment in vivo, which
preceded the induction of tumor regressions, suggesting that sustained
reduction of NAD is required for maximum efficacy. The kinetics of
NAD reduction as it relates to tumor cell viability has not been dem-
onstrated before in vivo but is consistent with in vitro observations
made with continuous exposure of GMX-1778 in the IM-9 multiple
myeloma cell line in which maximum NAD reduction occurred 16
and 52 hours before complete reduction of ATP production and cell
lysis, respectively [11]. Similar findings were recapitulated with
GNE-617 treatment in PC3 cells in which >90% NAD depletion
occurred with 24 hours, >90% reduction in ATP levels by 52 hours,
followed by cell death after ∼60 hours (DelNagro and O’Brien,
unpublished observations).
Similar to other NAMPT inhibitors such as AP0866 and GMX-
1778, we confirmed that in vitro NA does not inhibit the anti-growth
effects of GNE-617 in tumor cell lines that do not express NAPRT1.
Remarkably, however, we made the unexpected finding that three
NAPRT1-deficient xenograft models were protected from NAMPT
inhibition by GNE-617 when co-administered with NA in vivo. This
rescue phenomenon was also observed at doses of NA (30 mg/kg, twice
daily) that in mouse blood matches human exposures of a prescribed
oral dose (2000 mg) of niacin [20]. Importantly, loss of efficacy was
also observed with a second NAMPT inhibitor, GNE-618, when
co-dosed with NA in two patient-derived xenograft models. In one
of these models (STO-799), the loss of efficacy with NA co-treatment
in vivo was not predicted given that NA completely protected cells
from doses of GNE-618 that were greater than the EC90 when tumor
explants were grown ex vivo.
Collectively, our results suggest that NA can rescue the antitumor
effects ofNAMPT inhibitors in vivo. These results are, to a degree, con-
sistent with one study using an NAPRT1-deficient ovarian carcinoma
xenograft model (A2780) in which co-administration of NA with
APO866 decreased the life span of tumor-bearing mice to the number
of days animals survived with NA alone [8]. In this study, however, the
efficacy of APO866 at MTD was modest, and the resulting loss of
efficacy with NA co-treatment was compared to NA and not vehicle-
treated animals. Thus, the degree of NA rescue of TGI by APO866
in vivo was unclear. In contrast, a second study evaluating GMX-
1778 did not exhibit a significant difference in TGI in the presence
of NA in the NAPRT1-deficient HT-1080 xenograft model [11],
although, and consistent with our data, there was a trend toward
Figure 9. NAM co-treatment increases NAD levels and rescues anti-
proliferative effects of NAMPT inhibition in vitro. PC3 and MiaPaCa-2
tumor cell lines were exposed to GNE-617 (0.2 μM), NA (10 μM),
and/or NAM (2000 μM). (A and B) NAD levels were determined after
48 hours of treatment and measured by LC-MS/MS as described in
Materials andMethods section. ATP levels (C and D) and cell viability
(E and F) were assessed by CellTiter-Glo and CyQUANT assays, re-
spectively, after 96 hours of treatment as described in Materials
and Methods section. Comparisons between treatment groups
were performed using unpaired t test assuming unequal variances:
***P < .0001.
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decreased efficacy on NA co-treatment when GMX-1778 was dosed
at its MTD. However, NA was administered after GMX-1778
treatment and not co-administered with the NAMPT inhibitor, which,
based on our results, does lead to a moderate loss of in vivo efficacy [11].
Notably, the HT-1080 xenograft model tested in our study is
dependent on the dose of NA, since we did not observe loss of efficacy
of GNE-617 at a lower dose of NA (30 mg/kg) tested. Thus, it remains
possible that the timing of NA administration, dose of the NAMPT
inhibitor, or NA itself tested renders the HT-1080 model more resis-
tant to the rescue effects of NA co-treatment. Administration of NA
with GMX-1778 in the PC3 model, however, did result in a complete
loss of efficacy similar to observations made with GNE-617. The latter
underscores the importance of confirming the rescuability of NA on
in vivo efficacy of NAMPT inhibitors in multiple xenograft models,
which we have demonstrated in this report. Moreover, the ability
of NA to rescue in vivo efficacy does not appear to be unique to a
particular NAMPT inhibitor.
Importantly, while GNE-617 treatment reduced tumor NAD
levels by greater than 95% in vivo, co-administration of NA, which
completely rescued TGI, only increased tumor NAD levels to 15%
to 20% relative to untreated tumors. This observation is consistent
with our in vivo data demonstrating that a dose of GNE-617 that
can reduce tumor NAD levels by 80% was not efficacious, again
suggesting that sustained reduction of NAD by >95% is required
for maximum antitumor activity. Similar to NA, NAM co-treatment
with GNE-617 also resulted in a loss of efficacy and a modest increase
Figure 10. NAM co-treatment increases NAD levels and rescues antitumor effects of NAMPT inhibition in vivo. (A) PC3 tumor xenografts
were treated (Rx) orally for 5 days with vehicle control, NAM (twice daily), GNE-617 (once daily), or the combination of both agents at the
doses indicated. (B–D) PC3 tumor xenografts (n= 5 per group) were treated (Rx) orally for 5 days with vehicle control, NAM, GNE-617, or
the combination of both agents at the doses indicated, and tumors (B and C) or blood (D) was harvested 1 hour after the final dose
for NAD (B) and NAM (C and D) measurements by LC-MS/MS as described in Materials and Methods section. Comparisons between
treated groups and control (vehicle) were determined by Dunnett method: ***P < .0001. Comparisons between treatment groups were
performed using unpaired t test assuming unequal variances: ##P < .001, ###P < .0001.
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in NAD levels in NAPRT1-deficient tumor xenografts. Notably,
NAM, but not NA, co-treatment modestly increased NAD in
NAPRT1-deficient tumor cell lines in vitro while completely
reversing the antiproliferative effects of GNE-617. Therefore, our
in vitro data demonstrating rescuability by NAM translated well
in vivo and suggest that low levels of NAD are remarkably sufficient
to support tumor cell growth. The latter is also supported by the
observation that that 90% reduction of cellular NAD levels by
GMX-1778 is not sufficient to reduce viability in vitro [11]. Taken
together, the in vitro and in vivo data demonstrate the remarkably
high threshold for reduction of tumor NAD levels by an NAMPT
inhibitor required to induce efficacy.
Collectively, our data demonstrate complete protection from
NAMPT inhibition when NA is co-administered in vivo and further-
more demonstrates that protection is associated with regeneration of
tumor NAD and NAM levels in the absence of NAPRT1. Because
we were unable to detect any evidence of reexpression of NAPRT1 on
NA treatment that could account for its protection, one compelling
hypothesis is that rescuability is mediated by resupplying tumors
with NAD or NAD precursors provided exogenously by normal,
highly metabolic tissues such as the liver. In this case, the increase
in liver NAD in response to NA may be sufficient to provide tumor
cells with these metabolites to overcome the growth inhibitory effects
of GNE-617. Indeed, the work by Billington et al. demonstrated that
NIH-3T3 and SH-SYSY cells can uptake extracellular NAD in vitro at
physiologically relevant concentrations and rescue cell death induced
by FK866 on co-administration [22].
A second possibility is that increased liver NAM levels may pro-
vide an additional source of metabolites that enable NAD regeneration
in tumors through NAMPT itself. Indeed, NAM is the primary cir-
culating metabolite detected after intake and conversion of dietary
NA in the liver [23]. Given the competitive nature of NAMPT inhibi-
tors biochemically and structurally [24] (Oh et al., manuscript in
preparation), the resulting increase in tumor NAM levels may com-
pete with GNE-617 for binding to NAMPT. Consistent with this, a
co-crystal structure of GNE-617 bound in the NAMPT active site
suggests that the molecule will compete with NAM for binding
to the protein (Oh et al., manuscript in preparation). In addition,
previous biochemical experiments indicate that high NAM concen-
trations can negatively impact the ability of NAMPT inhibitors,
which are structurally related to GNE-617, to completely block
the function of the enzyme [25]. Similar to our observations in
NAPRT1-deficient tumor cell lines, NAM has been shown to
protect HepG2 human liver carcinoma cells in vitro from NAMPT
inhibition [26]. Thus, NAM itself may block the ability of GNE-617
to inhibitNAMPT effectively, thereby reactivating theNAMPT salvage
pathway to regenerate NAD in tumors in a positive feedback
manner. Finally, it is possible that addition of NA may cause changes
in intrinsic enzyme activity for another rate-limiting component of
the pathway.
In conclusion, NA rescues the antitumor effects of NAMPT in-
hibitors in vivo as a result of regeneration of NAD in NAPRT1-
deficient tumors. The data reported herein have important and direct
implications in the clinical development of NAMPT inhibitors in
terms of widening the therapeutic index by NA co-administration
and suggest that this strategy may not be effective in patients as ini-
tially proposed. Our work also underscores the need to fully assess
the impact of the complex in vivo metabolic macroenvironment when
evaluating the efficacy of drugs that target tumor metabolism.
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Figure W1. Expression ofNAMPT andNAPRT1 in tumor xenografts.
Untreated tumors were harvested and processed for Western blot
analysis to determine protein levels of NAMPT and NAPRT1 as
described in Materials and Methods section. The NAPRT1-proficient
Colo205 xenografts were used as positive control for NAPRT1
Western blot analysis.
Figure W2. Tolerability of GNE-617 in NAPRT1-proficient and NAPRT1-deficient tumor xenografts. (A–D) NAPRT1-proficient (A, HCT-116)
and NAPRT1-deficient (B, MiaPaCa-2; C, PC3; D, HT-1080) xenograft models were treated (Rx) orally with vehicle control or GNE-617 at the
doses indicated for 5 days (twice daily). (E and F) PC3 (E) and HT-1080 (F) tumor xenografts were treated orally with GNE-617 at the doses
indicated for 7 days (once daily). Percent change in body weights is relative to body weights of tumor-bearing mice at the beginning of
treatment and measured twice a week during the course of the study.
Figure W3. Efficacy of GNE-617 in the presence or absence of NA
in PC3 tumor xenografts after long-termdosing. Tumor-bearingmice
were treated (Rx) orally and once daily with vehicle control, GNE-617,
NA, or the combination of both agents at the doses indicated for
21 continuous days.
